Short Interest in Ascendis Pharma A/S (NASDAQ:ASND) Grows By 13.9%

Ascendis Pharma A/S (NASDAQ:ASND) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totalling 3,350,000 shares, a growth of 13.9% from the March 15th total of 2,940,000 shares. Based on an average daily volume of 375,400 shares, the short-interest ratio is currently 8.9 days.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ASND. GAMMA Investing LLC bought a new stake in shares of Ascendis Pharma A/S during the fourth quarter valued at about $25,000. US Bancorp DE increased its holdings in Ascendis Pharma A/S by 35.2% during the 4th quarter. US Bancorp DE now owns 284 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 74 shares during the period. Quadrant Capital Group LLC lifted its stake in Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 91 shares in the last quarter. Finally, Coppell Advisory Solutions LLC bought a new position in shares of Ascendis Pharma A/S in the second quarter worth $45,000.

Analyst Ratings Changes

A number of equities research analysts recently commented on ASND shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $173.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, April 1st. Wedbush increased their target price on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an “outperform” rating in a report on Thursday, February 8th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Monday, December 25th. JPMorgan Chase & Co. boosted their target price on Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 2nd. Finally, Jefferies Financial Group assumed coverage on Ascendis Pharma A/S in a research note on Wednesday, December 20th. They issued a “buy” rating and a $150.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $173.25.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND traded down $1.06 during trading hours on Tuesday, reaching $144.17. The stock had a trading volume of 154,198 shares, compared to its average volume of 374,875. The stock has a market cap of $8.39 billion, a P/E ratio of -15.65 and a beta of 0.50. The stock has a 50 day simple moving average of $149.10 and a 200 day simple moving average of $123.28. Ascendis Pharma A/S has a 12-month low of $66.03 and a 12-month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.15) by $0.49. The business had revenue of $148.62 million for the quarter, compared to analysts’ expectations of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. On average, equities analysts expect that Ascendis Pharma A/S will post -4.18 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.